Oct 09 2026 09:48 PM EST
AngioDynamics Shares Slide After Earnings Beat and CEO Transition
AngioDynamics (NASDAQ: ANGO) saw its shares tumble more than 20% on Tuesday despite reporting revenue and earnings that beat consensus estimates. The decline coincided with a leadership transition and a reaffirmation of FY 2027 guidance that left investors questioning the path to profitability.
For the quarter ended August 31 2026, the company generated $80.9 million in net sales, up 6.9 % YoY. Adjusted earnings per share were ‑$0.04, beating the consensus estimate of ‑$0.11. GAAP net loss narrowed to $7.1 million from $10.9 million a year earlier, and cash stood at $34.0 million with no debt. Management reaffirmed FY 2027 net‑sales guidance of $336 million‑$341 million and adjusted EPS of ‑$0.24 to ‑$0.29.
Earnings Beat Offsets Guidance Reaffirmation
Revenue growth was driven by the Med‑Tech segment, which posted a 13.2 % increase to $39.9 million. Adjusted EBITDA rose to $5.0 million from $2.2 million a year earlier, reflecting improving operating discipline. However, the company warned that gross margins would dip in the second half of FY 2027 because of tariff‑related expenses and a manufacturing transition, tempering enthusiasm around the top‑line beat.
CEO Succession Adds Short‑Term Uncertainty
The board announced on October 2 that President Eric Honroth will assume the role of chief executive on November 2, succeeding long‑time CEO Jim Clemmer. While the transition is described as orderly, investors reacted to the uncertainty surrounding strategic continuity, prompting a surge in options volume and a put‑call ratio above 1.0.
Med‑Tech Momentum Meets Margin Pressure
The Med‑Tech line, which includes the Auryon atherectomy platform and AlphaVac thrombectomy system, recorded four consecutive quarters of double‑digit growth (13 %, 19 %, 16.7 % YoY). Gross margin for the quarter improved to 59.4 %, up 410 bps YoY, but management flagged a projected decline to the 54‑55 % range in H2 FY 2027 due to a $1.3 million tariff expense and inflationary input costs.
Sector backdrop and competitive landscape
The peripheral vascular devices market is projected to reach $13.22 billion by 2031, expanding at a 5.7 % CAGR. Major rivals such as Boston Scientific and Medtronic continue to invest heavily in next‑generation thrombectomy and atherectomy technologies, raising the bar for product differentiation. Reimbursement constraints in the United States, including bundled‑payment ceilings for PAD treatment, add pressure on pricing and margins.
Risks and unanswered questions
Key risks include continued margin compression from tariffs and the ongoing manufacturing transition, the impact of a pending FDA warning letter on NanoKnife promotional language, and the ability of the new CEO to sustain the Med‑Tech growth trajectory. Additionally, the reaffirmed FY 2027 guidance leaves little upside in the near term, and the elevated put‑call ratio suggests a bearish bias that could exacerbate price volatility.